Product Images Losartan Potassium

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 6 images provide visual information about the product associated with Losartan Potassium NDC 68071-4454 by Nucare Pharmaceuticals,inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

pdp - 68071 4454 09 z15

pdp - 68071 4454 09 z15

This is information about a prescription drug called Losartan Potassium in tablet form, with an NDC (National Drug Code) number of 6807144540 and an AWP (Average Wholesale Price) of $23. It comes in a bottle of 90 tablets and its lot number is 000000 with an expiration date of 00-00. The Rx# for this product is 23025419. The label contains a warning to keep the product out of reach of children and to store it at a controlled temperature between 59°F-86°F. The text contains some errors and inconsistencies.*

Chemical Structure - spl image1 structure1

Chemical Structure - spl image1 structure1

Figure 1 - spl image2 figure1

Figure 1 - spl image2 figure1

This is a comparison between two medications, Atenolol and Losartan Potassium, for the primary endpoint in a study. The adjusted risk reduction was 13% with a p-value of 0.021. The graph displays the study duration in months.*

Figure 2 - spl image3 figure2

Figure 2 - spl image3 figure2

This appears to be a comparison of two medications, Atenolol and Losartan Potassium, with an adjusted risk reduction percentage of 25% and a p-value of 0.001. The chart shows the percentage of patients with fatal/non-fatal stroke over a period of 66 study months.*

Figure 3 - spl image4 figure3

Figure 3 - spl image4 figure3

Figure 4 - spl image5 figure4

Figure 4 - spl image5 figure4

This text represents the results of a clinical study comparing the effectiveness of Losartan Potassium to a placebo in reducing the risk of an event in patients. The table shows the percentage of patients with the event at different time intervals (0, 12, 24, 36, and 48 months) for both treatment groups. The risk reduction for Losartan Potassium compared to placebo is 16.1%, and the p-value for this difference is 0.022.*

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.